Login to Your Account



Genta's CLL Data Better; Don't Count Them Out'

By Randall Osborne


Tuesday, September 20, 2005
Genta Inc.'s ongoing bid to find a replacement partner for Genasense can only be helped by more positive news from its Phase III study testing the compound with chemotherapy against relapsed or refractory chronic lymphocytic leukemia. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription